Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Daiichi Sankyo to Terminates Vaccine Business Alliance with Sanofi in Japan
April 1, 2021
- Rohto to Invest in Kobe University Spin-Off to Develop Bio-Foundry
April 1, 2021
- GHIT Fund to Invest 2.3 Billion Yen in 10 Projects for Malaria, TB, Tropical Diseases
April 1, 2021
- Fujifilm Reorganizes Healthcare Biz Focusing on Biologics CDMO, Drug Development Support
April 1, 2021
- Astellas Integrates Audentes, Sets Up New In-House Unit for Gene Therapy
April 1, 2021
- Celgene Files Its 2nd CAR-T Therapy Ide-Cel in Japan: BMS
April 1, 2021
- Japan Trials Get Underway for AstraZeneca’s COVID-19 Antibody Therapy
April 1, 2021
- Lenvima/Keytruda Combo Accepted for EU Review for RCC, Endometrial Cancer
March 31, 2021
- Sumitovant Gets Entire Stake in Urovant: Sumitomo Dainippon
March 31, 2021
- Otsuka Partner Akebia Files HIF-PH Inhibitor Vadadustat in US
March 31, 2021
- JCR’s MPS I Drug Earns Orphan Status in Europe
March 31, 2021
- Nafamostat Inhalation Drug Now in Clinic for COVID-19: Daiichi Sankyo
March 31, 2021
- Xospata Shows Survival Benefits in Confirmatory AML Study in China, Other Regions: Astellas
March 31, 2021
- With Promotion Halt Lifted, Nichi-Iko Says to Launch Lyrica OD Generics on April 7
March 30, 2021
- Kyowa Kirin Grants All Worldwide Rights for Anti-LIGHT Antibody to Aevi
March 30, 2021
- Ohara Files Methotrexate Antidote in Japan
March 30, 2021
- Xtandi Gets EU Panel Backing for HSPC: Astellas
March 30, 2021
- Eisai Drops Numbers from New Mid-Term Plan; CEO Wants Value-Based Pricing for AD Meds
March 29, 2021
- Myrbetriq Earns US Approval for Pediatric NDO: Astellas
March 29, 2021
- AZ, Fujifilm to Codevelop Case Search System for Lung Cancer Patients Undergoing Chemoradiotherapy
March 29, 2021
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…